The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Dupixent has been approved for CSU in Japan and the United Arab Emirates (UAE) and is also under regulatory review in the European Union based on earlier trial readouts. Outside of Japan and the UAE, ...
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...
The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...
The potential treatment of chronic obstructive pulmonary disease (COPD) with Dupixent is anticipated to further enhance the drug's market presence. Moreover, TD Cowen emphasized the significant ...
CHICAGO, Nov. 4, 2024 /PRNewswire/ -- Today, the American Lung Association has launched the "Learning to Live with COPD" campaign, which aims to help people newly diagnosed with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback